Skip to main content

Table 4 SUCRA values and rankings produced based on all trials included in [29]

From: Spie charts for quantifying treatment effectiveness and safety in multiple outcome network meta-analysis: a proof-of-concept study

Treatment Outcome
Clear/nearly clear Mean change in DLQI PASI 75 Withdrawal due to adverse events
SUCRA Rank SUCRA Rank SUCRA Rank SUCRA Rank
Ixekizumab 0.99 1 0.70 3 0.96 1 0.14 7
Secukinumab 0.85 2 0.85 1 0.79 3 0.80 3
Infliximab 0.67 3 0.80 2 0.81 2 0.04 8
Ustekinumab 0.60 4 0.70 4 0.52 4 0.82 1
Adalimumab 0.46 5 0.51 5 0.49 5 0.81 2
Etanercept 0.28 6 0.31 6 0.28 6 0.46 6
Methotrexate 0.15 7 0.15 7 0.15 7 0.47 4
Placebo 0.00 8 0.00 8 0.00 8 0.47 5